RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration
- 16 September 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 61 (suppl 3), S155-S159
- https://doi.org/10.1093/cid/civ611
Abstract
Progress in tuberculosis clinical research is hampered by a lack of reliable biomarkers that predict progression from latent to active tuberculosis, and subsequent cure, relapse, or failure. Regional Prospective Observational Research in Tuberculosis (RePORT) International represents a consortium of regional cohorts (RePORT India, RePORT Brazil, and RePORT Indonesia) that are linked through the implementation of a Common Protocol for data and specimen collection, and are poised to address this critical research need. Each RePORT network is designed to support local, in-country tuberculosis-specific data and specimen biorepositories, and associated research. Taken together, the expected results include greater global clinical research capacity in high-burden settings, and increased local access to quality data and specimens for members of each network and their domestic and international collaborators. Additional networks are expected to be added, helping to spur tuberculosis treatment and prevention research around the world.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health
- NIH
- Indian Department of biotechnology
- The Ministry of science and Technology
- Indian Council of Medical Research
- NIAID
- Ministry of Health and Department of Science and Technology
- Indonesia National Institute of Health Research and Development
- NIAID
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- NIH
This publication has 8 references indexed in Scilit:
- Tuberculosis biomarkers discovery: developments, needs, and challengesThe Lancet Infectious Diseases, 2013
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionNew England Journal of Medicine, 2011
- Tuberculosis Biomarker and Surrogate Endpoint Research RoadmapAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Diagnostic and Management Challenges for Childhood Tuberculosis in the Era of HIVThe Journal of Infectious Diseases, 2007
- Data Standards: At the Intersection of Sites, Clinical Research Networks, and Standards Development InitiativesDrug Information Journal, 2007
- Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialThe Lancet, 2002
- Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 InfectionAnnals of Internal Medicine, 1997
- Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic FailureAnnals of Internal Medicine, 1997